Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Durvalumab”

729 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 729 results

Testing effectiveness (Phase 2)Looking for participantsNCT05844046
What this trial is testing

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

Who this might be right for
Hepatocellular Carcinoma
Enrico De Toni 83
Large-scale testing (Phase 3)Active Not RecruitingNCT03528694
What this trial is testing

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle-invasive Bladder Cancer
AstraZeneca 1,018
Testing effectiveness (Phase 2)Active Not RecruitingNCT03875573
What this trial is testing

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:

Who this might be right for
Luminal B
Jules Bordet Institute 147
Large-scale testing (Phase 3)Study completedNCT04642469
What this trial is testing

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

Who this might be right for
Carcinoma, Non- Small Cell Lung
AstraZeneca 30
Early research (Phase 1)Study completedNCT03089645
What this trial is testing

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

Who this might be right for
Advanced Solid Tumors
MedImmune LLC 39
Early research (Phase 1)Ended earlyNCT02997332
What this trial is testing

Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Cancers
Gustave Roussy, Cancer Campus, Grand Paris 14
Testing effectiveness (Phase 2)Looking for participantsNCT06548412
What this trial is testing

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Who this might be right for
Metastatic Biliary Tract Cancer
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Testing effectiveness (Phase 2)Looking for participantsNCT05440864
What this trial is testing

Durvalumab and Tremelimumab in Resectable HCC

Who this might be right for
Hepatocellular Carcinoma
University Health Network, Toronto 28
Large-scale testing (Phase 3)Active Not RecruitingNCT06992609
What this trial is testing

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

Who this might be right for
Small Cell Lung Carcinoma
AstraZeneca 68
Testing effectiveness (Phase 2)Study completedNCT02821754
What this trial is testing

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Who this might be right for
Biliary Tract NeoplasmsLiver CancerHepatocellular Carcinoma+2 more
National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT04348045
What this trial is testing

Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.

Who this might be right for
Metastatic Pancreatic Adenocarcinoma
GERCOR - Multidisciplinary Oncology Cooperative Group 307
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Testing effectiveness (Phase 2)UnknownNCT04083365
What this trial is testing

Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer

Who this might be right for
RECTAL CANCER
AUSL Romagna Rimini 100
Not applicableActive Not RecruitingNCT06008353
What this trial is testing

A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil

Who this might be right for
Extensive-stage Small-cell Lung Cancer
AstraZeneca 60
Testing effectiveness (Phase 2)Study completedNCT03345810
What this trial is testing

Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

Who this might be right for
Carcinoma, Non-Small-Cell LungMetastatic Lung CancerNon Small Cell Lung Cancer+2 more
AIO-Studien-gGmbH 200
Testing effectiveness (Phase 2)Looking for participantsNCT06911255
What this trial is testing

Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma (HCC)Unresectable Hepatocellular Carcinoma
Yoon Jun Kim 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT04716946
What this trial is testing

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

Who this might be right for
NSCLCNon-small Cell Lung CancerLung Cancer+5 more
Memorial Sloan Kettering Cancer Center 13
Large-scale testing (Phase 3)Study completedNCT02273375
What this trial is testing

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Canadian Cancer Trials Group 1,415
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07226063
What this trial is testing

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

Who this might be right for
Hepatocellular CarcinomaLiver Cancer
Amit Mahipal 16
Next Page